...
首页> 外文期刊>Vaccine >Costing RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda: A generalizable approach drawing on publicly available data
【24h】

Costing RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda: A generalizable approach drawing on publicly available data

机译:在布基纳法索,加纳,肯尼亚,塞内加尔,坦桑尼亚和乌干达对RTS,S进行成本估算:一种基于公开数据的通用方法

获取原文
获取原文并翻译 | 示例
           

摘要

Recent results from the phase 3 trial of RTS,S/AS01 malaria vaccine show that the vaccine induced partial protection against clinical malaria in infants and children; given the high burden of the disease it is currently considered for use in malaria endemic countries. To inform adoption decisions the paper proposes a generalizable methodology to estimate the cost of vaccine introduction using routinely collected and publicly available data from the cMYP, UNICEF, and WHO-CHOICE. Costing is carried out around a set of generic activities, assumptions, and inputs for delivery of immunization services adapted to a given country and deployment modality to capture among other factors the structure of the EPI program, distribution model, geography, and demographics particular to the setting. The methodology is applied to estimate the cost of RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda. At an assumed vaccine price of $5 per dose and given our assumptions on coverage and deployment strategy, we estimate total economic program costs for a 6-9 months cohort within $23.11-$28.28 per fully vaccinated child across the 6 countries. Net of procurement, costs at country level are substantial; for instance in Tanzania these could add as much as $4.2 million per year or an additional $2.4 per infant depending on the level of spare capacity in the system. Differences in cost of vaccine introduction across countries are primarily driven by differences in cost of labour. Overall estimates generated with the methodology result in costs within the ranges reported for other new vaccines introduced in SSA and capture multiple sources of heterogeneity in costs across countries. Further validation with data from field trials will support use of the methodology while also serving as a validation for cMYP and WHO-CHOICE as resources for costing health interventions in the region. (C) 2015 The Authors. Published by Elsevier Ltd.
机译:RTS,S / AS01疟疾疫苗三期试验的最新结果表明,该疫苗可诱导部分预防婴幼儿临床疟疾;考虑到该疾病的高负担,目前考虑将其用于疟疾流行国家。为了为采用决定提供依据,本文提出了一种可推广的方法,该方法使用来自cMYP,UNICEF和WHO-CHOICE的常规收集的和公开可用的数据来估算疫苗引入的成本。成本核算是围绕一组通用活动,假设和投入而进行的,这些活动,假设和投入适用于给定国家/地区和部署方式的免疫服务,以捕获除其他因素外的EPI计划的结构,分配模型,地理和人口统计。设置。该方法用于估算在布基纳法索,加纳,肯尼亚,塞内加尔,坦桑尼亚和乌干达的RTS,S引入成本。以每剂疫苗5美元的假定疫苗价格以及我们对覆盖率和部署策略的假设,我们估算6个国家/地区6-9个月队列中每个完全接种疫苗的儿童的经济计划总费用在23.11-28.28美元之间。扣除采购后,国家一级的费用是巨大的;例如在坦桑尼亚,根据系统的备用容量水平,这些费用每年可能会增加420万美元或每名婴儿额外增加2.4美元。各国疫苗引进成本的差异主要是由劳动力成本的差异驱动的。用该方法得出的总估算值导致成本在SSA中引入的其他新疫苗报告的范围之内,并体现了各国成本的多种异质性。利用实地试验数据进行的进一步验证将支持该方法的使用,同时也可作为对cMYP和WHO-CHOICE的验证,作为该地区卫生干预措施成本的资源。 (C)2015作者。由Elsevier Ltd.发布

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号